## 121814\_121815\_121816 Kruuse Blood Collection Tube Heparin Lithium

Issued: 21/06/2024 Version: 1.0.0

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1. Product identifier

Trade name: 121814\_121815\_121816 Kruuse Blood Collection Tube Heparin Lithium

Substance name: Lithium Heparin

**CAS No:** 9045-22-1 **EC No:** 241-543-5

#### Article no

Article no	Description
121811	
121812	
121813	

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended uses:** Veterinary use.

### 1.3. Details of the supplier of the safety data sheet

## **Supplier**

Company: Jørgen Kruuse A/S Address: Havretoften 4

Zip code: 5550
City: Langeskov
Country: DENMARK

E-mail: Export@kruuse.com
Phone: +4572141414
Homepage: www.kruuse.com

### 1.4. Emergency Telephone Number

Tel: +45 72141414 (Jørgen Kruuse A/S)

The emergency telephone is open between 8 a.m. and 4 p.m. on workdays.

## **SECTION 2: Hazards identification**

### 2.1. Classification of the substance or mixture

**CLP-classification:** Skin Sens. 1;H317 Resp. Sens. 1;H334

Most serious harmful effects: May cause an allergic skin reaction. May cause allergy or asthma symptoms or breathing

difficulties if inhaled.

## 121814\_121815\_121816 Kruuse Blood Collection Tube Heparin Lithium

Issued: 21/06/2024 Version: 1.0.0

### 2.2. Label elements

## **Pictograms**



Signal word: Danger

**Hazard Statements** 

H317 May cause an allergic skin reaction.

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Precautionary statements** 

P261 Avoid breathing vapours.
P280 Wear protective gloves.

P304+340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P333+313 If skin irritation or rash occurs: Get medical advice/attention.

P342+311 If experiencing respiratory symptoms: Call a POISON CENTER/doctor.
P501 Dispose of contents/container in accordance with local regulation.

#### 2.3. Other hazards

The product does not contain any PBT or vPvB substances.

Endocrine disrupting properties: None known.

## **SECTION 3: Composition/information on ingredients**

## 3.1. Substances

Substance	CAS No./ EC No./ REACH Reg. No.	Concentration	Notes	CLP-classification
Lithium Heparin	9045-22-1 241-543-5	90 - 100 %		Skin Sens. 1;H317 Resp. Sens. 1;H334

Please see section 16 for the full text of H- / EUH-phrases.

## **SECTION 4: First aid measures**

### 4.1. Description of first aid measures

**Inhalation:** Seek fresh air, wash out mouth with water and blow nose thoroughly. Seek medical advice

in case of breathing difficulties.

Ingestion: Wash out mouth thoroughly and drink 1-2 glasses of water in small sips. Seek medical

advice in case of persistent discomfort.

Skin contact: Remove contaminated clothing. Wash skin with soap and water. Seek medical advice in

case of persistent discomfort.

**Eye contact:** Flush with water (preferably using eye wash equipment) until irritation subsides. Seek

medical advice if symptoms persist.

**General:** When obtaining medical advice, show the safety data sheet or label.

### 4.2. Most important symptoms and effects, both acute and delayed

May cause sensitisation by inhalation and skin contact. Symptoms include cold, sneezing, breathing difficulties and hives. Reddening, swelling, blistering and ulceration may develop on the skin - often slowly.

## 4.3. Indication of any immediate medical attention and special treatment needed

## 121814 121815 121816 Kruuse Blood Collection Tube Heparin Lithium

Issued: 21/06/2024 Version: 1.0.0

Treat symptoms. No special immediate treatment required.

## **SECTION 5: Firefighting measures**

## 5.1. Extinguishing media

Suitable extinguishing media: Extinguish with powder, foam, carbon dioxide or water mist. Use water or water mist to cool

non-ignited stock.

Unsuitable extinguishing

media:

Do not use water stream, as it may spread the fire.

### 5.2. Special hazards arising from the substance or mixture

Product decomposes in fire conditions or when heated to high temperatures, and inflammable and toxic gases may be released.

## 5.3. Advice for firefighters

Move containers from danger area if it can be done without risk. Avoid inhalation of vapour and flue gases - seek fresh air. Wear Self-Contained Breathing Apparatus (SCBA) with a chemical protection suit only where personal (close) contact is likely.

### **SECTION 6: Accidental release measures**

### 6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel: Stay upwind/keep distance from source. Avoid inhalation/keep a distance. Wear gloves.

Wear safety goggles if there is a risk of dust contact with eyes.

For emergency responders: In addition to the above: Protective suit equivalent to EN 368, type 3, is recommended.

## 6.2. Environmental precautions

Prevent spillage from entering drains and/or surface water.

### 6.3. Methods and material for containment and cleaning up

Sweep up/collect spills for possible reuse or transfer to suitable waste containers. Wipe up minor spills with a damp cloth.

## 6.4. Reference to other sections

See section 13 for instructions on disposal. See section 8 for type of protective equipment.

## **SECTION 7: Handling and storage**

### 7.1. Precautions for safe handling

Wash hands before breaks, before using restroom facilities, and at the end of work. Running water and eye wash equipment must be available.

## 7.2. Conditions for safe storage, including any incompatibilities

Store safely, out of reach of children and away from food, animal feeding stuffs, medicines, etc. Store in a dry area. Keep in tightly closed original packaging.

## 7.3. Specific end use(s)

None.

## **SECTION 8: Exposure controls/personal protection**

## 121814\_121815\_121816 Kruuse Blood Collection Tube Heparin Lithium

Issued: 21/06/2024 Version: 1.0.0

### 8.1. Control parameters

Occupational exposure limit: Contains no substances subject to reporting requirements.

Measuring methods: Compliance with occupational exposure limits may be checked by occupational hygiene

measurements.

Legal basis: Commission Directive 2000/39/EC (Occupational Exposure Limits) as subsequently

> amended. Last amended by Commission Directive 2019/1831/EU. Directive 2004/37/EC (Exposure to carcinogens or mutagens at work) as subsequently amended. Last amended by Directive 2024/869/EU. Directive 2009/148/EC (Exposure to asbestos at work) as

subsequently amended. Last amended by Directive 2023/2668/EU.

### 8.2. Exposure controls

Appropriate engineering controls:

Wear the personal protective equipment specified below.

eye/face protection:

Personal protective equipment, Wear safety goggles if there is a risk of dust contact with eyes. Eye protection must

conform to EN 166/16321.

hand protection:

Personal protective equipment, Wear gloves. Type of material and thickness: Nitrile rubber/ 0.11 mm. Penetration time:

>=480 min. Gloves must conform to EN 374.

The suitability and durability of a glove is dependant on usage, e.g. frequency and duration of contact, glove material thickness, functionality and chemical resistance. Always seek

advice from the glove supplier.

respiratory protection:

Personal protective equipment, Wear respiratory protective equipment with P2 filter when performing dusty work. Respiratory protection must conform to one of the following standards: EN 136/140/145.

**Environmental exposure** 

controls:

Ensure compliance with local regulations for emissions.

### **SECTION 9: Physical and chemical properties**

### 9.1. Information on basic physical and chemical properties

Parameter	Value/unit	
State	Powder	
Colour	White	
Odour	No data	
Solubility	Soluble in the following: Water.	

Parameter	Value/unit	Remarks
Odour threshold	No data	
Melting point	180 - 185 °C	
Freezing point	No data	
Initial boiling point and boiling range	No data	
Flammability (solid, gas)	No data	
Flammability limits	No data	
Explosion limits	No data	
Flash Point	No data	
Auto-ignition temperature	No data	
Decomposition temperature:	No data	
pH (solution for use)	No data	
pH (concentrate)	8 - 9	50 g/l H2O (20 °C)
Kinematic viscosity	No data	
Viscosity	No data	
Partition coefficient n-octonol/water	No data	
Vapour pressure	No data	

## 121814\_121815\_121816 Kruuse Blood Collection Tube Heparin Lithium

Issued: 21/06/2024 Version: 1.0.0

Density	No data	
Relative density	No data	
Vapour density	No data	
Relative density (sat. air)	No data	
Particle characteristics	No data	

### 9.2. Other information

Other Information: None.

## **SECTION 10: Stability and reactivity**

## 10.1. Reactivity

No known data.

### 10.2. Chemical stability

The product is stable when used in accordance with the supplier's directions.

### 10.3. Possibility of hazardous reactions

None known.

#### 10.4. Conditions to avoid

None known.

## 10.5. Incompatible materials

None known.

### 10.6. Hazardous decomposition products

None, if stored at the recommended storage conditions.

### **SECTION 11: Toxicological information**

## 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute toxicity - oral: Ingestion may cause discomfort. The product does not have to be classified. Test data are

not available.

**Acute toxicity - dermal:** The product does not have to be classified. Test data are not available.

**Acute toxicity - inhalation:** The product does not have to be classified. Test data are not available.

**Skin corrosion/irritation:** May cause slight irritation. The product does not have to be classified. Test data are not

available.

Serious eye damage/eye

irritation:

Temporary irritation. The product does not have to be classified. Test data are not available.

Respiratory sensitisation or

skin sensitisation:

May cause sensitisation by inhalation and skin contact. Symptoms include cold, sneezing, breathing difficulties and hives. Reddening, swelling, blistering and ulceration may develop

on the skin - often slowly.

**Germ cell mutagenicity:** The product does not have to be classified. Test data are not available.

**Carcinogenic properties:** The product does not have to be classified. Test data are not available.

**Reproductive toxicity:** The product does not have to be classified. Test data are not available.

## 121814\_121815\_121816 Kruuse Blood Collection Tube Heparin Lithium

Issued: 21/06/2024 Version: 1.0.0

**Single STOT exposure:** Inhalation of vapours is irritating to the upper airways.

**Repeated STOT exposure:** The product does not have to be classified. Test data are not available.

**Aspiration hazard:** The product does not have to be classified. Test data are not available.

### 11.2. Information on other hazards

Endocrine disrupting

properties:

None known.

Other toxicological effects: None known.

## **SECTION 12: Ecological information**

### 12.1. Toxicity

The product does not have to be classified. Test data are not available.

#### 12.2. Persistence and degradability

Test data are not available.

## 12.3. Bioaccumulative potential

Test data are not available.

## 12.4. Mobility in soil

Test data are not available.

### 12.5. Results of PBT and vPvB assessment

The product does not contain any PBT or vPvB substances.

### 12.6. Endocrine disrupting properties

None known.

### 12.7. Other adverse effects

None known.

## **SECTION 13: Disposal considerations**

### 13.1. Waste treatment methods

Avoid discharge to drain or surface water. If this product as supplied becomes a waste, it meets the criteria of a hazardous waste (Dir. 2008/98/EU). Collect spills and waste in closed, leak-proof containers for disposal at the local hazardous waste site. Uncleansed packaging is to be disposed of via the local waste-removal scheme. Empty, cleansed packaging should be disposed of for recycling.

Category of waste: EWC code: Depends on line of business and use, for instance 16 03 05\* organic wastes

containing hazardous substances

Absorbent/cloth contaminated with the product: EWC code: 15 02 02\* absorbents, filter materials (including oil filters not otherwise specified), wiping cloths, protective clothing

contaminated by hazardous substances

## **SECTION 14: Transport information**

**14.1. UN number or ID number:** Not applicable. **14.4. Packing group:** Not applicable.

## 121814\_121815\_121816 Kruuse Blood Collection Tube Heparin Lithium

Issued: 21/06/2024

Version: 1.0.0

14.2. UN proper shipping

name:

Not applicable.

14.5. Environmental

hazards:

Not applicable.

14.3. Transport hazard

class(es):

Not applicable.

## 14.6. Special precautions for user

None.

## 14.7. Maritime transport in bulk according to IMO instruments

Not applicable.

## **SECTION 15: Regulatory information**

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Special Provisions: Special care should be applied for employees under the age of 18. Young people under the

age of 18 may not carry out any work causing harmful exposure to this product.

Covered by:

Council Directive (EC) on the protection of young people at work.

### 15.2. Chemical Safety Assessment

Other Information: Chemical safety assessment has not been performed.

### **SECTION 16: Other information**

### Version history and indication of changes

Version	Revision date	Responsible	Changes
1.0.0	21/06/2024	LJO	-

**Abbreviations:** PBT: Persistent, Bioaccumulative and Toxic

vPvB: Very Persistent and Very Bioaccumulative

STOT: Specific Target Organ Toxicity

Other Information: This safety data sheet has been prepared for and applies to this product only. It is based on

our current knowledge and the information that the supplier was able to provide about the product at the time of preparation. The safety data sheet complies with applicable law on preparation of safety data sheets in accordance with 1907/2006/EC (REACH) as

subsequently changed.

**Training advice:** A thorough knowledge of this safety data sheet should be a prerequisite condition.

Classification method: Calculation based on the hazards of the known components.

**Hazard statements** 

H317 May cause an allergic skin reaction.

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

SDS is prepared by

Company: Bureau Veritas Solution Denmark A/S

Address: Oldenborggade 25-31

Zip code: 7000 City: Fredericia

# 121814\_121815\_121816 Kruuse Blood Collection Tube Heparin Lithium

Issued: 21/06/2024 Version: 1.0.0

Country: DENMARK

E-mail: infohse@bureauveritas.com

Phone: +45 77 31 10 00 Homepage: www.bureauveritas.dk

Country: EU